Indian generics giant Sun Pharmaceuticals has announced plans to acquire US biotech company Concert through for a total of $576m.
The transaction is expected to close within the first quarter of 2023.
Sun Forwards Specialty Strategy With $576m Concert Acquisition
Sun’s Nabs Concert, Picking Up Firm’s ‘Potential Best-In-Class’ Deuruxolitinib
Listen to this article
Sun has struck a $576m deal to acquire Concert Pharmaceuticals, picking up lead product candidate deuruxolitinib as part of an acquisition that advances the Indian firm’s specialty pivot.
Stay ahead of every shift in generics and biosimilars.
More from Deals
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
More from Business
- • By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
- • By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains